Editorial review · United States
Tesamorelin
Source review:
Approval and product status
An FDA-approved product exists for a narrow indication
The two approved products are not interchangeable. Egrifta SV and Egrifta WR are approved, non-substitutable formulations with product-specific labeling. Tesamorelin sold or compounded outside those products is not automatically equivalent.
This is the status described in the dated review. It is not a live FDA database check.
What was measured in people?
- Health outcomes · Strong
- Phase 3 trials support visceral-adipose-tissue reduction in the labeled HIV population.
- Body effects · Strong
- The approved label characterizes IGF-1 response, exposure, and product-specific use.
A change in a hormone or body signal does not by itself prove a health benefit.
Limits that matter
Not independently medically reviewed. This tool does not recommend treatment.
This prescription drug has benefits for a specific group and important monitoring requirements. No dosing, cycling, stacking, or performance-use guidance is provided.
Still unknown: These results do not establish general fat loss, muscle gain, anti-aging benefit, athletic recovery, or equivalent outcomes from compounded products.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval claims, with their sources
“Tesamorelin is an approved general weight-loss drug.”
Misleading. The label specifically says it is not indicated for weight-loss management.
Applies to: The current Egrifta SV and Egrifta WR labels.
Exact product records in this review
These are selected records, not every product or form. A route means how a product enters the body.
Egrifta SV
- Form
- 2 mg single-dose vial
- Route
- Subcutaneous
- Use and limits
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
Published label: 2024 label
Read the published Egrifta SV FDA label (PDF)Egrifta WR
- Form
- 11.6 mg single-patient-use multidose vial
- Route
- Subcutaneous
- Use and limits
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
Published label: March 2025
Read the published Egrifta WR FDA label (PDF)What the research shows
Controlled trials in adults with HIV-associated abdominal fat accumulation found less visceral fat, which is fat around internal organs. The Egrifta SV and Egrifta WR labels say the products are not indicated for weight-loss management and that long-term cardiovascular safety has not been established. Their formulations are not substitutable.
Read all Tesamorelin claims and their limitsSources used in the full review
A source is not support for every claim. Use the claim links above or the full review to check what each source supports.
- EGRIFTA SV (tesamorelin) prescribing information
U.S. Food and Drug Administration · Drug label · 2024
Source accessed
- EGRIFTA WR (tesamorelin) prescribing information
U.S. Food and Drug Administration · Drug label · 2025
Source accessed
- Tesamorelin in HIV-associated abdominal fat accumulation
PubMed · Journal of Acquired Immune Deficiency Syndromes · Randomized trial · 2010
Source accessed
- 2026 Prohibited List
World Anti-Doping Agency · Anti-doping · 2026
Source accessed